Epinephrine Market Size, Share, New Innovative With Top Key Players- ALK ABELLO, Amneal Pharma, Kaleo, Emirade, Aurum Pharma, Adamis Pharmaceuticals

The Epinephrine market is expected to reach US$ 4,207.88 Mn in 2027 from US$ 2,247.87 Mn in 2019. The market is estimated to grow with a CAGR of 8.3% from 2019-2027.

The report provides trends prevailing in the global epinephrine market and the factors driving the market along with those that act as hindrances. The increasing anaphylaxis cases and the introduction of the generic versions of epinephrine are expected to boost market growth over the years. However, the lack of availability of epinephrine auto-injectors and their low-cost alternatives are likely to restrain the growth of the market.

Download sample PDF Report at: https://bit.ly/2AL6MFN

The global epinephrine market, based on the type, is segmented into auto-injectors, prefilled syringes and ampoules & vials. The auto-injectors segment led the epinephrine market in 2019, and; it is expected to retain its dominance during the forecast period.

Key factors that are driving growth of the market are increasing anaphylaxis cases and introduction of generic version of epinephrine. However, lack of availability of epinephrine auto injectors and their low-cost alternatives is likely to have a negative impact on the growth of the market in the coming years.

The epinephrine market majorly consists of the players such as MYLAN N.V., Abbott, ALK ABELLO, Amneal Pharma, Kaleo, LINCOLN MEDICAL LTD (BioProject), Teva Pharmaceuticals Ltd, Adamis Pharmaceuticals Corporation (Novartis AG), Emirade, and Aurum Pharma (Ethypharm Group Company). Various companies are focusing on organic strategies such as product launches, expansion, investments among other strategies. Inorganic growth strategies witnessed in the market were acquisition, agreement and partnerships & collaborations. For instance, in July 2019, Novartis AG launched SYMJEPI autoinjectors in the US market. The product was launched through Sandoz which is part of Novartis.

The incidence of anaphylaxis is increasing worldwide; according to the NICE, the UK registers an estimated death count of 20 due to anaphylaxis, every year. Moreover, as per the European Academy of Allergy and Clinical Immunology data, ~150 million Europeans suffer from chronic allergic diseases, every year. Anaphylaxis is a generalized allergic reaction; thus the rising incidence of allergies is also leading to the surge in the number of anaphylaxis cases. A large population suffers from various allergies worldwide. For example, as per Allergy Facts by the American College of Allergy, Asthma & Immunology, more than 50 million Americans experience different types of allergies every year.

Epinephrine is the first-line treatment in anaphylaxis cases. As per studies, it prevents or reduces upper airway mucosal edema, i.e., laryngeal edema, hypotension, and shock through vasoconstrictor effects. Additionally, it has important bronchodilator effects and cardiac inotropic as well as chronotropic effects. Thus, increasing anaphylactic incidences drive the growth of the market.

During recent years, the demand for the auto-injectors have increased due to the advantages offered by the device. It helps in faster administration and helps in reducing allergic reactions quickly. Based on the application, anaphylaxis is the larger contributor for the growth of epinephrine market. And the market for epinephrine is growing due to wide on-line distribution of the product. The on-line distribution helps people to buy product and keep it in stock, and assist them to be prepared for an allergic reaction anywhere at any time.

Ask for Discount at: https://bit.ly/2AHTtWC

Some of the activities undertaken by the companies, which have promoted its growth are, majorly organic developments. Companies such as Amneal Pharmaceuticals, Inc., Kaleo Inc., and Novartis AG among others have been implementing various organic strategies that have helped the growth of the company and in turn have brought about various changes in the epinephrine market. The companies have utilized strategies such as product launches, expansion, investments among other strategies that has enabled them to strengthen their product portfolio and area expansion for their own and market’s growth.

Table of Content:
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Epinephrine Market – By Product Type
1.3.2 Global Epinephrine Market – By Application
1.3.3 Global Epinephrine Market – By Distribution Channel
1.3.4 Global Epinephrine Market – By Geography
2. Epinephrine Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Epinephrine– Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America – PEST Analysis
4.2.2 Epinephrine Market in Europe: PEST Analysis
4.2.3 Epinephrine Market in APAC: PEST Analysis
4.2.4 Middle East & Africa – PEST Analysis
4.2.5 South & Central America – PEST Analysis
4.3 Expert Opinion
5. Epinephrine Market – Key Dynamics
5.1 Drivers
5.1.1 Increasing Number of Anaphylaxis Cases
5.1.2 Introduction of generic version of epinephrine
5.2 Restraints
5.2.1 Lack of Availability of Epinephrine Auto-Injectors and Their Low-Cost Alternatives
5.3 Opportunities
5.3.1 Growing Pipeline of Epinephrine
5.4 Trends
5.4.1 Novel Drug Delivery Systems
5.5 Impact Analysis

Buy Now This report at: https://bit.ly/2Xz9W8N

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

This release was published on openPR.